当前位置: 首页 >> 检索结果
共有 62504 条符合本次的查询结果, 用时 2.9689782 秒

1101. Oxidative Stress Causes Mitochondrial and Electrophysiologic Dysfunction to Promote Atrial Fibrillation in Pitx2+/- Mice.

作者: Tuerdi Subati.;Kyungsoo Kim.;Zhenjiang Yang.;Matthew B Murphy.;Joseph C Van Amburg.;Isis L Christopher.;Owen P Dougherty.;Kaylen K Woodall.;Charles D Smart.;Joyce E Johnson.;Agnes B Fogo.;Venkataraman Amarnath.;Vineet Agrawal.;Joey V Barnett.;Jeffrey E Saffitz.;Katherine T Murray.
来源: Circ Arrhythm Electrophysiol. 2025年18卷3期e013199页
The strongest genetic risk factors for atrial fibrillation (AF) are DNA variants on chromosome 4q25 near the transcription factor gene PITX2 (Pitx2:Paired-like homeodomain transcription factor 2). Mice deficient in Pitx2 (Pitx2+/-) have increased AF susceptibility, although the molecular mechanism(s) remains controversial. Pitx2 encodes a transcription factor that activates an antioxidant response to promote cardiac repair. Increased reactive oxygen species causing oxidation of polyunsaturated fatty acids generates reactive lipid dicarbonyl moieties that adduct to proteins and other macromolecules to promote cellular injury. We tested the hypothesis that oxidative stress, and specifically isolevuglandins, the most reactive lipid dicarbonyls identified, are increased in the setting of Pitx2 deficiency to promote proarrhythmic remodeling and AF.

1102. Subcutaneous Implantable Defibrillators in Young Patients: Arrhythmias, Complications, and Physical Activity.

作者: Pietro Francia.;Matteo Ziacchi.;Federico Migliore.;Paolo De Filippo.;Antonio Dello Russo.;Stefano Viani.;Antonio Rapacciuolo.;Giulio Falasconi.;Carmen Adduci.;Giovanni Bisignani.;Luca Checchi.;Giuseppe Busacca.;Luca Santini.;Carlo Lavalle.;Valeria Ilia Calvi.;Antonio Curcio.;Massimo Silvetti.;Antonio Pangallo.;Marco Carbonaro.;Davide Giorgi.;Raimondo Pittorru.;Mariolina Lovecchio.;Sergio Valsecchi.;Mauro Biffi.;Antonio D'Onofrio.;Antonio Pelliccia.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷3期e013365页
The safety of subcutaneous implantable cardioverter defibrillator (S-ICD) recipients who lead active lifestyles and engage in recreational sports is unknown. We aimed to evaluate the association between lifestyle and recreational sports and the occurrence of arrhythmia- and device-related complications, appropriate and inappropriate shocks in S-ICD recipients.

1103. Response by Bhimaraj et al to Letter Regarding Article, "Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the DanGer Shock Trial?".

作者: Arvind Bhimaraj.;Arthur R Garan.;Manreet K Kanwar.
来源: Circ Heart Fail. 2025年18卷4期e012655页

1104. Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support.

作者: Lara S Schlender.;Marco Ochs.;Reza Wakili.;Robert Stöhr.;Fabian Emrich.;Thomas Walther.;Jan Gummert.;Michiel Morshuis.;David M Leistner.;Maria Papathanasiou.
来源: Circ Heart Fail. 2025年18卷4期e011639页

1105. Variations in the Medical Device Authorization and Reimbursement Landscape: A Case Study of 2 Cardiovascular Devices Across 4 Countries.

作者: Marta M Williams.;Nathan R Smith.;Carin A Uyl-de Groot.;Corstiaan A den Uil.;Joseph S Ross.;Mohamed O Mohamed.;Mamas A Mamas.;Amitava Banerjee.;Dennis T Ko.;Bruce Landon.;Peter Cram.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷4期e011636页
The authorization process and coverage/reimbursement mechanisms for medical devices play critical roles in device adoption and usage. However, international variation in these processes remains poorly characterized, especially with regard to data transparency and the effects of reimbursement on usage.

1106. Letter by Dalzell and Cannon Regarding Article, "Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the DanGer Shock Trial?".

作者: Jonathan R Dalzell.;Jane A Cannon.
来源: Circ Heart Fail. 2025年18卷4期e012607页

1107. Characteristics of Patients With the Arrhythmogenic Mitral Valve Prolapse Syndrome and Sudden Cardiac Arrest and Sustained Ventricular Arrhythmias.

作者: Apurba Chakrabarti.;John R Giudicessi.;Fatima M Ezzeddine.;Francesca N Delling.;Shalini Dixit.;Yoo Jin Lee.;Daniele Muser.;Silvia Magnani.;Aniek Van Wijngaarden.;Nina Ajmone Marsan.;Marc A Miller.;Jonathan Gandhi.;Maria G Trivieri.;Jonaz Font.;Raphael Martins.;James A McCaffrey.;Pasquale Santangeli.;Francis E Marchlinski.;Himal Chapagain.;Don Mathew.;Krishna Kancharla.;Faisal F Syed.;Ahad Abid.;Lukasz Cerbin.;Wendy S Tzou.;Lohit Garg.;Domenico G Della Rocca.;Andrea Natale.;Sanghamitra Mohanty.;Seth H Sheldon.;Ling Kuo.;Kristina H Haugaa.;Eivind W Aabel.;Andres Enriquez.;Shingo Maeda.;Amrish Deshmukh.;Michael Ghannam.;Frank Bogun.;Michael J Ackerman.;Jackson J Liang.
来源: Circ Arrhythm Electrophysiol. 2025年18卷3期e013099页
Patients with arrhythmogenic mitral valve prolapse syndrome are at increased risk for life-threatening ventricular arrhythmias, but studies have been limited by small sample sizes. We sought to assemble an international arrhythmogenic mitral valve prolapse syndrome registry to delineate the clinical, imaging, and treatment characteristics of patients with arrhythmogenic mitral valve prolapse syndrome who survived sudden cardiac arrest (SCA) or had sustained ventricular tachycardia (VT) or ventricular fibrillation.

1108. Fast Degradation of MecciRNAs by SUPV3L1/ELAC2 Provides a Novel Opportunity to Tackle Heart Failure With Exogenous MecciRNA.

作者: Xu Liu.;Qinwei Wang.;Xinya Li.;Yan Yang.;Yuqi Deng.;Xiaolin Wang.;Peipei Wang.;Liang Chen.;Likun Ma.;Ge Shan.
来源: Circulation. 2025年151卷17期1272-1290页
Circular RNAs derived from both nuclear and mitochondrial genomes are identified in animal cells. Mitochondria-encoded circular RNAs (mecciRNAs) are attracting more attention, and several members of mecciRNAs have already been recognized in regulating mitochondrial functions. Mitochondria dysfunctions are well-known to participate in heart failure (HF). This study was designed to investigate the RNA metabolism of mecciRNAs and the relevant roles and potential application of mecciRNAs in HF.

1109. Sane Approach to Optimizing the Workload in Remote Monitoring of Cardiovascular Implantable Electronic Devices.

作者: Markus Sane.;Toni Jäntti.;Annukka Marjamaa.;Elina Pennanen.;Charlotte Aura.;Eeva Torvinen.;Leena Karjalainen.;Pekka Raatikainen.;Jarkko Karvonen.
来源: Circ Arrhythm Electrophysiol. 2025年18卷3期e013078页
Remote monitoring offers an effective and safe method for monitoring patients with cardiovascular implantable electronic devices. The downside of remote monitoring is the overflow of the data. Since many of the remote monitoring transmissions are nonactionable, optimizing alert transmissions could partly overcome this problem.

1110. Independent External Evaluation of Pediatric Hypertrophic Cardiomyopathy Risk Scores in Predicting Severe Ventricular Arrhythmias.

作者: Marie Wilkin.;Diala Khraiche.;Elena Panaioli.;Margaux Pontailler.;Olivier Raisky.;Eloi Marijon.;Damien Bonnet.;Victor Waldmann.
来源: Circ Arrhythm Electrophysiol. 2025年18卷3期e012932页
Sudden cardiac death is the most common cause of death in childhood hypertrophic cardiomyopathy (HCM). Recently, 2 risk scores have been developed to estimate the 5-year risk of sudden cardiac death. We aimed to assess their respective performances in an independent cohort.

1111. Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.

作者: Jonathan H Kim.;Aaron L Baggish.;Benjamin D Levine.;Michael J Ackerman.;Sharlene M Day.;Elizabeth H Dineen.;J Sawalla Guseh.;Andre La Gerche.;Rachel Lampert.;Matthew W Martinez.;Michael Papadakis.;Dermot M Phelan.;Keri M Shafer.; .
来源: Circulation. 2025年151卷11期e716-e761页
Larry A. Allen, MD, MHS, FAHA, FACC; Mats Börjesson, MD, PhD, FACC; Alan C. Braverman, MD, FACC; Julie A. Brothers, MD; Silvia Castelletti, MD, MSc, FESC; Eugene H. Chung, MD, MPH, FHRS, FAHA, FACC; Timothy W. Churchill, MD, FACC; Guido Claessen, MD, PhD; Flavio D'Ascenzi, MD, PhD; Douglas Darden, MD; Peter N. Dean, MD, FACC; Neal W. Dickert, MD, PhD, FACC; Jonathan A. Drezner, MD; Katherine E. Economy, MD, MPH; Thijs M.H. Eijsvogels, PhD; Michael S. Emery, MD, MS, FACC; Susan P. Etheridge, MD, FHRS, FAHA, FACC; Sabiha Gati, BSc (Hons), MBBS, PhD, MRCP, FESC; Belinda Gray, BSc (Med), MBBS, PhD; Martin Halle, MD; Kimberly G. Harmon, MD; Jeffrey J. Hsu, MD, PhD, FAHA, FACC; Richard J. Kovacs, MD, FAHA, MACC; Sheela Krishnan, MD, FACC; Mark S. Link, MD, FHRS, FAHA, FACC; Martin Maron, MD; Silvana Molossi, MD, PhD, FACC; Antonio Pelliccia, MD; Jack C. Salerno, MD, FACC, FHRS; Ankit B. Shah, MD, MPH, FACC; Sanjay Sharma, BSc (Hons), MBChB, MRCP (UK), MD; Tamanna K. Singh, MD, FACC; Katie M. Stewart, NP, MS; Paul D. Thompson, MD, FAHA, FACC; Meagan M. Wasfy, MD, MPH, FACC; Matthias Wilhelm, MD.

1112. Bleeding and New Malignancy Diagnoses After Anticoagulation for Atrial Fibrillation: A Population-Based Cohort Study.

作者: Kavi Grewal.;Xuesong Wang.;Peter C Austin.;Cynthia A Jackevicius.;Inbar Nardi-Agmon.;Dennis T Ko.;Douglas S Lee.;Paaladinesh Thavendiranathan.;Michael Fradley.;Paul Dorian.;Husam Abdel-Qadir.
来源: Circulation. 2025年151卷11期773-782页
Bleeding after starting anticoagulation for atrial fibrillation (AF) may be the first sign of malignancy, especially in elderly individuals. There are no recommendations to guide investigations for malignancy after new-onset bleeding after anticoagulation for AF. Our objective was to determine the association of bleeding after starting oral anticoagulation for AF with new diagnoses of malignancy in a population-wide sample.

1113. Principles for the Future of Biomedical Research in the United States and Optimizing the National Institutes of Health: A Presidential Advisory From the American Heart Association.

作者: Joseph C Wu.;Donna K Arnett.;Ivor J Benjamin.;Mark A Creager.;Robert A Harrington.;Joseph A Hill.;P Michael Ho.;Steven R Houser.;Stephanie Scarmo.;Svati H Shah.;Gordon F Tomaselli.; .
来源: Circulation. 2025年151卷14期e867-e876页
Groundbreaking achievements in science and medicine have contributed to reductions in cardiovascular disease and stroke mortality over the past 7 decades. Many of these advances were supported through investments by the National Institutes of Health, the global leader in funding biomedical research. This public investment has produced important economic returns, including supporting >400 000 jobs and roughly $93 billion in economic activity in the United States. Unfortunately, public funding has not kept pace with the burden of disease or rates of inflation. As the nation's oldest and largest volunteer organization dedicated to fighting heart disease and stroke, research is critical to the American Heart Association's mission. Given the American Heart Association's unique position in representation of patients, clinicians, and scientists and as a research funder, we offer the following principles to optimize the future of the US biomedical research enterprise in general and the National Institutes of Health in particular. Specifically, the United States should continue to prioritize innovative and impactful research; to improve efficiency and transparency in its peer review process; to lead in translating evidence into practice; to support the current and future biomedical workforce; and to ensure robust and reliable public investment for the future. The American Heart Association reiterates our strong support for the National Institutes of Health and federal agencies that fund and implement biomedical and population-based research initiatives, which yield important economic returns. These agencies are vital to support today's current and future health challenges, to drive foundational science, to improve patient health, to reduce the global disease burden, to address upstream and preventive strategies, and to improve the value of our public health and health care investments.

1114. Natural History, Phenotype Spectrum, and Clinical Outcomes of Desmin (DES)-Associated Cardiomyopathy.

作者: Babken Asatryan.;Marina Rieder.;Brittney Murray.;Steven A Muller.;Crystal Tichnell.;Alessio Gasperetti.;Richard T Carrick.;Emily Joseph.;Doris G Leung.;Anneline S J M Te Riele.;Stefan L Zimmerman.;Hugh Calkins.;Cynthia A James.;Andreas S Barth.
来源: Circ Genom Precis Med. 2025年18卷2期e004878页
Pathogenic/likely pathogenic (LP) desmin (DES) variants cause heterogeneous cardiomyopathy and skeletal myopathy phenotypes. Limited data suggest a high incidence of major adverse cardiac events (MACEs), including cardiac conduction disease, sustained ventricular arrhythmias (VA), and heart failure (HF) events (HF hospitalization, left ventricular assist device/cardiac transplant, HF-related death) in patients with pathogenic/LP DES variants. However, pleiotropic presentation and small cohort sizes have limited clinical phenotype and outcome characterization. We aimed to describe the natural history, phenotype spectrum, familial penetrance and outcomes in patients with pathogenic/LP DES variants through a systematic review and individual patient data meta-analysis using published reports.

1115. Analysis of TTN Truncating Variants in >74 000 Cases Reveals New Clinically Relevant Gene Regions.

作者: Matteo Vatta.;Ellen Regalado.;Michael Parfenov.;Dan Swartzlander.;Andrea Nagl.;Meghan Mannello.;Rachel Lewis.;Daniel Clemens.;John Garcia.;Rachel E Ellsworth.;Ana Morales.;Yi-Lee Ting.;Swaroop Aradhya.
来源: Circ Genom Precis Med. 2025年18卷2期e004982页
Truncating variants (TTNtvs) in the titin (TTN) gene have been associated with cardiomyopathies or arrhythmias (C/A) and autosomal recessive neuromuscular diseases (NM). However, the clinical significance of TTNtvs across the entire coding sequence of TTN has not been comprehensively assessed. The purpose of this study was to examine the burden of TTNtvs in C/A and NM cases compared with controls in the genome aggregation database.

1116. Prognostic Relevance of Type 4a Myocardial Infarction and Periprocedural Myocardial Injury in Patients With Non-ST-Segment-Elevation Myocardial Infarction.

作者: Matteo Armillotta.;Luca Bergamaschi.;Pasquale Paolisso.;Marta Belmonte.;Francesco Angeli.;Angelo Sansonetti.;Andrea Stefanizzi.;Davide Bertolini.;Francesca Bodega.;Sara Amicone.;Lisa Canton.;Damiano Fedele.;Nicole Suma.;Andrea Impellizzeri.;Francesco Pio Tattilo.;Daniele Cavallo.;Ornella Di Iuorio.;Khrystyna Ryabenko.;Andrea Rinaldi.;Gabriele Ghetti.;Francesco Saia.;Cinzia Marrozzini.;Gianni Casella.;Paola Rucci.;Alberto Foà.;Carmine Pizzi.
来源: Circulation. 2025年151卷11期760-772页
Periprocedural myocardial injury (PMI) with or without type 4a myocardial infarction (MI) might occur in patients with non-ST-segment-elevation MI (NSTEMI) after percutaneous coronary intervention (PCI). This study investigated the incidence and prognostic relevance of these events, according to current definitions, in patients with NSTEMI undergoing PCI. The best cardiac troponin I (cTnI) threshold of PMI for prognostic stratification is also suggested.

1117. HALT and Catch Fire: Understanding the Histopathologic Processes of Hypoattenuated Leaflet Thickening in TAVR.

作者: Rahul Gupta.;Matthew W Sherwood.;Amit N Vora.
来源: Circ Cardiovasc Interv. 2025年18卷2期e015088页

1118. Intravascular Imaging Predictors Associated With Cardiovascular Events After Complex PCIs.

作者: Joo Myung Lee.;Sang Yoon Lee.;Woochan Kwon.;Seung-Jae Lee.;Jong-Young Lee.;Seung Hun Lee.;Doosup Shin.;Sang Yeub Lee.;Sang Min Kim.;Kyeong Ho Yun.;Jae Young Cho.;Chan Joon Kim.;Hyo-Suk Ahn.;Chang-Wook Nam.;Hyuck-Jun Yoon.;Yong Hwan Park.;Wang Soo Lee.;Ki Hong Choi.;Taek Kyu Park.;Jeong Hoon Yang.;Seung-Hyuk Choi.;Hyeon-Cheol Gwon.;Young Bin Song.;Joo-Yong Hahn.; .
来源: Circ Cardiovasc Interv. 2025年18卷2期e014920页
Intravascular imaging-guided percutaneous coronary intervention (PCI) has been shown to improve clinical outcomes in patients with complex coronary artery lesions compared with angiography-guided PCI. However, the prognostic impact of suboptimal findings on intravascular imaging such as stent underexpansion, malapposition, or dissection is unclear in the era of contemporary drug-eluting stents.

1119. Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening.

作者: Yu Sato.;Sho Torii.;Kenji Kawai.;Kazuyuki Yahagi.;Matthew Kutyna.;Rika Kawakami.;Takao Konishi.;Aimee E Vozenilek.;Hiroyuki Jinnouchi.;Atsushi Sakamoto.;Hiroyoshi Mori.;Anne Cornelissen.;Masayuki Mori.;Takamasa Tanaka.;Teruo Sekimoto.;Robert Kutys.;Saikat Kumar B Ghosh.;John K Forrest.;Michael J Reardon.;Maria E Romero.;Frank D Kolodgie.;Renu Virmani.;Aloke V Finn.
来源: Circ Cardiovasc Interv. 2025年18卷2期e014523页
Hypoattenuated leaflet thickening (HALT) is believed to reflect leaflet thrombosis; however, no systematic histological examination of HALT has ever been performed. The aim of this study was to evaluate histological findings of explanted self-expanding transcatheter aortic bioprosthetic valves from clinical trials and to compare microCT findings of suspected HALT with histology findings of valve thrombosis and its characterization over time.

1120. Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in CTEPH: Insights From the RACE Trial.

作者: Christian Gerges.;Mitja Jevnikar.;Philippe Brenot.;Laurent Savale.;Antoine Beurnier.;Hélène Bouvaist.;Olivier Sitbon.;Elie Fadel.;Athénaïs Boucly.;Denis Chemla.;Gérald Simonneau.;Marc Humbert.;David Montani.;Xavier Jaïs.; .
来源: Circ Cardiovasc Interv. 2025年18卷2期e014785页
Riociguat and balloon pulmonary angioplasty (BPA) improve hemodynamics in inoperable chronic thromboembolic pulmonary hypertension. Importantly, comparative effects of riociguat and BPA on different components of right ventricular (RV) afterload and function remain not fully elucidated.
共有 62504 条符合本次的查询结果, 用时 2.9689782 秒